Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. Article

Corral Sánchez, María Dolores, Galán Gómez, Víctor, Sastre Urgelles, Ana et al. (2021). Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. . 38(5), 504-509. 10.1080/08880018.2021.1889730

cited authors

  • Corral Sánchez, María Dolores; Galán Gómez, Víctor; Sastre Urgelles, Ana; Plaza López de Sabando, Diego; Rubio Aparicio, Pedro; Martínez Martínez, Leopoldo; Alonso Gamarra, Eduardo; Pozo Kreilinger, José Juan; Regojo Zapata, Rita María; López Gutiérrez, Juan Carlos; Antolín Alvarado, Eugenia; Gómez Martín, Felipe; Sánchez Torres, Ana María; Marín Manzano, Elena; González Del Valle, Luis; Pérez-Martínez, Antonio

authors

abstract

  • Infantile fibrosarcoma (IFS) is a rare pediatric tumor which often presents the ETV6-NTRK3 gene fusion. NTRK3 encodes the neurotrophin-3 growth factor receptor tyrosine kinase, a druggable therapeutic target. Selective tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib, have shown efficacy and safety in the treatment of IFS. We report a case of an abdominal IFS diagnosed in a newborn associated with an aortic aneurysm that was successfully treated with larotrectinib without relevant adverse effects.

publication date

  • August 1, 2021

keywords

  • Abdominal Neoplasms
  • Aortic Aneurysm, Abdominal
  • Female
  • Fibrosarcoma
  • Humans
  • Infant
  • Infant, Newborn
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines

Digital Object Identifier (DOI)

Medium

  • Print-Electronic

start page

  • 504

end page

  • 509

volume

  • 38

issue

  • 5